首页|期刊导航|Cancer Innovation|Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma:A Retrospective Study

Treatment Outcomes With Novel Targeted and Immunotherapeutic Regimens in CAYA Hodgkin Lymphoma:A Retrospective StudyOA

中文摘要

Background:To evaluate the efficacy and safety of novel chemotherapy regimens,including brentuximab vedotin(BV)and immune checkpoint inhibitors(ICIs),in children,adolescents,and young adults(CAYA)with Hodgkin lymphoma(HL).Methods:A retrospective analysis was conducted on untreated Stage IIB(bulky),III,or IV HL patients(≤24 years)who were admitted to Cancer Hospital of the Chinese Academy of Medical Sciences and Beijing Children''s Hospital,Capital Medical University,from 2017 to 2024.The cohort compared conventional regimens with BV-based therapies(BV-AVD±R).Furthermore,the efficacy and safety of ICIs were evaluated in relapsed/refractory cHL patients receiving second-line or later therapy.Results:In this comparison between BV and conventional regimens,182 patients were enrolled.The median follow-up was 38 months.No significant differences were observed in objective response rate(ORR)(96.4%vs 95.4%,p=0.927)or progression-free survival(PFS)rate(92.8%vs 95.3%,p=0.466).However,the incidence of Grade 4 hematologic toxicity was significantly higher with conventional therapy compared to BV-AVD±R(61.2%vs 25.6%,p<0.001).The BV-AVD group alone achieved a significantly higher ORR than the BV-AVD+R group(100%vs.93.9%,p=0.047),while there was no significant difference in PFS rate.However,the BV-AVD+R group exhibited a significantly higher incidence of Grade 3-4 hematologic toxicities(78.8%vs.20.0%,p=0.023).Immune checkpoint inhibitors was well-tolerated with infrequent adverse events,and 18/19 cases(94.7%)demonstrated treatment efficacy.Conclusion:For patients with stage II Hodgkin lymphoma presenting with bulky disease,as well as those with stage III-IV disease,the BV-AVD regimen is recommended as first-line therapy,given its more favorable toxicity profile.Although ICIs represent a promising therapeutic approach,existing studies are constrained by limited sample sizes.Future research should focus on expanding patient cohorts to refine treatment strategies and ultimately improve clinical outcomes.

Mengqing Xie;Meng Yuan;Mengwei Ren;Jing Tian;Shengyu Zhou;Xiaohui He;Yan Qin;Peng Liu;Jianliang Yang;Mengyuan Han;Fei Ma;Sheng Yang;Sidan Li

Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaHematology Center,Beijing Children''s Hospital,Capital Medical University,Beijing,China Department of Pediatric,Beijing Jishuitan Hospital,Capital Medical University,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaHematology Center,Beijing Children''s Hospital,Capital Medical University,Beijing,China Department of Pediatric,Beijing Shijitan Hospital,Capital Medical University,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,ChinaDepartment of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

医药卫生

adolescent and young adultbrentuximab vedotinHodgkin lymphomaimmune checkpoint inhibitors

《Cancer Innovation》 2026 (2)

P.91-100,10

National Key Research and Development Program of China,Grant/Award Number:2024YFA1107400National Natural Science Foundation of China,Grant/Award Number:82370142CAMS Innovation Fund for Medical Sciences,Grant/Award Number:2022-I2M-C&T-B-068CSCO-Allist Research Fund,Grant/Award Number:Y-2021AST/ms-0058。

10.1002/cai2.70050

评论